Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance

被引：0
|
作者：
Lucien Torlot
Anna Jarzab
Johanna Albert
Ágnes Pók-Udvari
Arndt Stahler
Julian Walter Holch
Marco Gerlinger
Volker Heinemann
Frederick Klauschen
Thomas Kirchner
Jörg Kumbrink
Bernhard Küster
Andreas Jung
机构：
[1] Ludwig-Maximilians-University (LMU),Institute of Pathology
[2] German Cancer Consortium (DKTK),Chair or Proteomics and Bioanalytics
[3] Technical University of Munich,Department of Hematology, Oncology, and Cancer Immunology
[4] Charité - Universitätsmedizin Berlin,Department of Medicine III
[5] Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,Comprehensive Cancer Center Munich (CCCM)
[6] German Cancer Consortium (DKTK),Translational Oncogenomics Lab
[7] LMU Hospital,Barts Cancer Institute
[8] LMU Hospital,Gastrointestinal Cancer Unit
[9] The Institute of Cancer Research,undefined
[10] Queen Mary University of London,undefined
[11] St Bartholomew’s Hospital,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Colorectal cancer; EPHA2; Cetuximab resistance; Molecular oncology; Proteomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：669 / 682
页数：13
相关论文
共 50 条
  • [1] Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
    Torlot, Lucien
    Jarzab, Anna
    Albert, Johanna
    Pok-Udvari, Agnes
    Stahler, Arndt
    Holch, Julian Walter
    Gerlinger, Marco
    Heinemann, Volker
    Klauschen, Frederick
    Kirchner, Thomas
    Kumbrink, Joerg
    Kuester, Bernhard
    Jung, Andreas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 669 - 682
  • [2] EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
    Miao, Benchun
    Ji, Zhenyu
    Tan, Li
    Taylor, Michael
    Zhang, Jianming
    Choi, Hwan Geun
    Frederick, Dennie T.
    Kumar, Raj
    Wargo, Jennifer A.
    Flaherty, Keith T.
    Gray, Nathanael S.
    Tsao, Hensin
    CANCER DISCOVERY, 2015, 5 (03) : 274 - 287
  • [3] EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
    Martini, Giulia
    Cardone, Claudia
    Vitiello, Pietro Paolo
    Belli, Valentina
    Napolitano, Stefania
    Troiani, Teresa
    Ciardiello, Davide
    Della Corte, Carminia Maria
    Morgillo, Floriana
    Matrone, Nunzia
    Sforza, Vincenzo
    Papaccio, Gianpaolo
    Desiderio, Vincenzo
    Paul, Mariel C.
    Moreno-Viedma, Veronica
    Normanno, Nicola
    Rachiglio, Anna Maria
    Tirino, Virginia
    Maiello, Evaristo
    Latiano, Tiziana Pia
    Rizzi, Daniele
    Signoriello, Giuseppe
    Sibilia, Maria
    Ciardiello, Fortunato
    Martinelli, Erika
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (04) : 845 - 855
  • [4] EphA2: A promising therapeutic target in breast cancer
    Ping Zhao
    Dewei Jiang
    Yunchao Huang
    Ceshi Chen
    Journal of Genetics and Genomics, 2021, 48 (04) : 261 - 267
  • [5] EphA2: A promising therapeutic target in breast cancer
    Zhao, Ping
    Jiang, Dewei
    Huang, Yunchao
    Chen, Ceshi
    JOURNAL OF GENETICS AND GENOMICS, 2021, 48 (04) : 261 - 267
  • [6] EPHA2: A novel target for prostate cancer treatment
    Zeng, G
    Hu, ZQ
    Zhang, SB
    Li, L
    Baldridge, LA
    Kao, CH
    Gardner, TA
    Koch, MO
    Ulbright, TM
    Eble, JN
    Cheng, L
    JOURNAL OF UROLOGY, 2004, 171 (04): : 482 - 482
  • [7] EpHA2 is an essential driver of invasion and a novel target in KRAS mutant colorectal cancer
    Dunne, Philip D.
    McArt, Darragh G.
    Blayney, Jaine K.
    Dasgupta, Sonali
    Salto-Tellez, Manuel
    Johnston, Patrick G.
    Van Schaeybroeck, Sandra
    CANCER RESEARCH, 2014, 74 (19)
  • [8] The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).
    Dasgupta, Sonali
    Van Schaeybroeck, Sandra
    Dunne, Philip
    McArt, Darragh
    Fenning, Cathy
    Ong, Chee Wee
    Arthur, Ken
    Salto-Tellez, Manuel
    Wilson, Richard H.
    Johnston, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] EPHA2/MAPK pathway confers acquired resistance of afatinib in gastric cancer
    Chen, Z.
    Liu, Z.
    Gao, J.
    Shen, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 27 - 27
  • [10] Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
    Koch, Heiner
    Busto, M. Estela Del Castillo
    Kramer, Karl
    Medard, Guillaume
    Kuster, Bernhard
    JOURNAL OF PROTEOME RESEARCH, 2015, 14 (06) : 2617 - 2625
12345